Biotech Values

[DewDiligence]

I have been using quarterly overhead at ~$20MM. I think it will be closer to $25MM by the end of '11.

Such a distinction is inconsequential in the overall scheme of things. In the unlikely (IMO) event that Teva gets FDA approval for Lovenox, MNTA will presumably adjust its operating costs to a level commensurate with lower revenues.